TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Primary disease is leukemia or MDS.~2. Patients receive haploidentical stem cell transplantation.~3. Both patients and donors are CMV seropositive (IgG positive).~4. Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative.~Exclusion Criteria:~1. Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol.~2. Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Donor-derived CMVpp65-specific T cells (Type: EXPERIMENTAL): Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \< 18 years~* American Society of Anesthesiologists risk I-II~* patients undergoing to Gastroscopy or Colonoscopy~Exclusion Criteria:~* significant systemic disease~* allergic reactions to any of study drugs~* chronic use of opioids or psychiatric disorders~* pregnancy~* Mallampati score \> 2~* age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- propofol group (Type: EXPERIMENTAL): 70 patients (35 upper endoscopy - 35 colonoscopy)
- midazolam group (Type: ACTIVE_COMPARATOR): 70 patients (35 upper endoscopy - 35 colonoscopy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patients aged 50 years or older~* a medical claim of EP~* a prescription claim for a 5ARI and AB (provided both are within 180 days of index date)~* continuously eligible for 6 months prior to and at least 12 months after index prescription date.~Exclusion Criteria:~* diagnosis of prostate or bladder cancer~* any prostate-related surgical procedure within 5 months of index date~* prescription claim for finasteride indicative of male pattern baldness~* 5ARI therapy initiated prior to initiating AB therapy

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early 5ARI Initiation (Type: None): Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
- Late 5ARI Initiation (Type: None): Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cough attributed to URTI such as the common cold~* 2-5 years of age~* moderate to severe day cough according to questionnaire (score at least 3 on all 3 questions relating to day cough) considering the day prior to enrollment.~* moderate to severe night cough score according to questionnaire (score at least 3 of 2 of the three questions relating to the evaluation of nocturnal cough (frequency of nocturnal cough, impact of the sleep of the child and impact on the sleep of the parent)~* signature of informed consent~Exclusion Criteria:~* Children with the diagnosis of diseases of the lower respiratory tract: inflammation of the larynx, trachea, bronchi, pneumonia, asthma, sinusitis, allergic rhinitis, as well as heart disease.~* Children who received cough medicines or drugs containing antihistamines the day prior to study entry.~* Known hypersensitivity to honey or any other component of the experimental product such as Grindelia, Helichrysum, essential oils natural flavourings of Lemon, Sweet Orange, Myrtle; Lemon natural flavouring~* Children who received any steroid preparation (spray nozzle , or syrup , or other similar the day before study entry )~* Known sensitivity to carbocysteine specifically to the comparator Mucolit~* gastric ulcer

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- protective cough syrup (Type: EXPERIMENTAL): syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)
- carbocisteine cough syrup (Type: ACTIVE_COMPARATOR): Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women with poor ovarian response candidate for ICSI~* women with spontaneous normal menstrual cycle~* normal uterine cavity~Exclusion Criteria:~* women with ovarian cysts~* endometriosis~* hydrosalpinx~* endocrinological disorders as hyperprolactinemia, thyroid or adrenal disorders.~* Couples with azospermic male partner~* those with severe uncontrolled medical or metabolic disorders

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- single trigger (Type: ACTIVE_COMPARATOR): 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
- Dual trigger (Type: ACTIVE_COMPARATOR): 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lupron Depot In The Treatment of Central Precocious Puberty

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of isosexual central precocious puberty with onset of Tanner scores of Stage II for breast or pubic hair earlier than age 8.0 years in girls or Stage II for pubic hair or genitalia earlier than 9.0 years in boys.~* Confirmation of diagnosis by a pubertal response to a gonadotropin-releasing hormone (GnRH) stimulation test (LH \> 10 U/L at baseline).~* Chronological age less than 9.0 years in girls or less than 10.0 years in boys at time of first dosing.~* Bone age advanced at least 1 year beyond the chronological age at entry into the study.~* The condition may be idiopathic or secondary to another lesion. If secondary, therapy of the primary condition will have been undertaken and stabilized.~* No evidence of abnormal pituitary, adrenal, thyroid and gonadal function except for premature secretion of gonadotropins.~Exclusion Criteria:~* Irradiation to the central nervous system.~* Prior therapy with medroxyprogesterone acetate and/or with any GnRH analog (including prior treatment with daily subcutaneous and depot formulations of leuprolide acetate).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant has a diagnosis of MDD as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Trial Version (SCID-5-CT), with symptoms that have been present for at least a 4-week period.~2. Participant is in good physical health and has no clinically significant findings, as determined by the Investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests.~3. Participant has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of ≥28 and a HAM-D total score of ≥20 at Screening and Day 1 (prior to dosing).~Exclusion Criteria:~1. Participant has attempted suicide associated with the current episode of MDD.~2. Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.~3. Participant has had vagus nerve stimulation, electroconvulsive therapy, or has taken ketamine (including esketamine) within the current major depressive episode.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SAGE-217 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females with CDAD~* Females must use adequate contraception~* Signed informed consent~Exclusion Criteria:~* Life-threatening CDAD~* Toxic megacolon~* Pregnant~* Concurrent use of diarrheal agents~* Participation in other trials

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Vancomycin
- 2 (Type: EXPERIMENTAL): PAR-101/OPT-80

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* pressure support ventilation or CPAP~* respiratory rate \> 35.min-1~* respiratory rate/tidal volume \> 105~Exclusion Criteria:~* vasoactive agents (dopamine lower than 5 mcg.kg-1.min-1 is not considered as vasoactive agent)~* body temperature \> 38 °C~* Glasgow Coma Scale \< 9~* FIO2 \> 0.6~* PEEP \> 10 cmH2O~* pH \< 7.30

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 4 Pillars Toolkit for Adolescent Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For clinical sites: inclusion criterion includes~  1. an appropriate adolescent population: e.g., adolescents aged 11 to 17 years~ 2. currently using an EMR~ 3. having and keeping immunization data within a EMR or registry.~Exclusion Criteria:~* For clinical sites: the exclusion criteria is consistent SOP use for the vaccines being studied or known much higher than average immunization rates.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Intervention: Toolkit (Type: EXPERIMENTAL): 4 Pillars Toolkit
- No Intervention: Standard practice (Type: NO_INTERVENTION): 11 Clinical Practices \[control sites\]

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has successfully completed a previous trial with SPM 927 in diabetic neuropathy and, in the investigator's opinion, would benefit from long-term administration of SPM 927.~* Subject has stable, good or fair diabetic control (HbA1c ≤10% ).~Exclusion Criteria:~* Subject has other conditions that cause neuropathic pain at least as severe as the diabetic pain, i.e. peripheral arterio-vascular disease.~* Subject receives treatment for seizures.~* Subject has had an amputation related to diabetes, other than toe amputation.~* Subject has major skin ulcers.~* Subject has clinically significant ECG abnormalities.~* Subject expects to take during the study: TCAs, mexiletine hydrochloride, lidoderm patch, tramadol, AEDs, dextromethorphan, opioids, capsaicin, skeletal muscle relaxants, benzodiazepines or over-the-counter medications with centrally acting properties.~* Subject has laboratory values which are outside the normal range and judged by the investigator to be clinically significant.~* Subject has liver function tests (AST, ALT, alkaline phosphatase, total bilirubin, or GGT) ≥ 2x ULN at Visit 1.~* At Visit 1, subject has impaired renal function, i.e., creatinine clearance (ClCr) is lower than 60 mL/min.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 4 to 17 years old, inclusive~* Moderate to severe pain (i.e. FPS-R or vNRS score of 4 or more)~* Requires parenteral opioid analgesic to treat their pain, as decided by treating physician~Exclusion Criteria:~* Allergy or known contraindication to receiving opioids~* Receipt of any opioid or benzodiazepine within preceding 6 hours~* Presence of intranasal obstruction that cannot be cleared readily~* Cannot speak English or Spanish~* Patient unlikely to be able to complete self-report measures of pain or questionnaires~* Known liver or kidney problems~* Currently critically ill~* Chronic pain condition (e.g. sickle cell disease, fibromyalgia)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal hydromorphone (Type: EXPERIMENTAL): Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Liver transplant between 6 months and 10 years prior to the screening visit~* Hepatitis C virus (HCV) genotype 1 subtype b infection confirmed at screening~* Screening HCV ribonucleic acid level greater than 10,000 IU/mL~* HCV treatment-naïve participants must not have received post orthotopic liver transplant treatment with any approved or investigational drug for the treatment of HCV~* Receiving stable immunosuppressant therapy (ie, no change in dose in the last month) with cyclosporine (only allowed in Part 1) or tacrolimus for more than 3 months prior to the screening visit~Exclusion Criteria:~* Evidence of acute or chronic hepatic decompensation after the liver transplantation (including ascites, bleeding varices or hepatic encephalopathy)~* Any liver disease of non-HCV etiology, including current evidence of graft rejection except the presence of liver steatosis~* Any other clinically significant disease that in the opinion of the investigator would be exacerbated by the known effects of ribavirin~* Coinfection with HCV of another genotype than genotype 1b, HIV type 1 or 2 (positive HIV-1 or HIV-2 antibodies test at screening), and hepatitis B virus (hepatitis B surface antigen positive)~* Multi-organ transplant that included heart, lung, pancreas, or kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 (Type: EXPERIMENTAL): Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
- Part 2 (Type: EXPERIMENTAL): Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a recreational opioid user who is NOT physically dependent on opioids based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) criteria, and the Naloxone Challenge. A recreational opioid user is defined as recreationally abusing opioids for non-therapeutic purposes (i.e., for psychoactive effects) on at least 10 occasions within the last year and at least once in the 12 weeks prior to Visit 1.~* Subject is in generally good health as determined by medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead electrocardiogram (ECG).~Exclusion Criteria:~* Has a history or current diagnosis of substance dependence (excluding caffeine and nicotine), as assessed by the Investigator using the DSM IV-TR criteria.~* Has participated in, is currently participating in, or is seeking treatment for substance- and/or alcohol-related disorders (excluding nicotine and caffeine).~* History or presence of any clinically significant illness (e.g., cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.~* Has a known allergy or history of hypersensitivity to morphine sulfate, opioids in general, naltrexone hydrochloride (HCl) or similar compounds and/or the known excipients in the investigational drug products.~* Has any condition in which an opioid is contraindicated (e.g., significant respiratory depression, acute or severe bronchial asthma or hypercarbia, or is suspected of having paralytic ileus).~* Females who are pregnant, lactating, or are planning to become pregnant during the course of the study. Females with a positive serum pregnancy test at Visit 1 or at any subsequent study visit will be excluded from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- MS Contin (morphine sulfate, controlled release) (Type: ACTIVE_COMPARATOR): None
- EMBEDA (morphine sulfate / naltrexone hydrochloride) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete